The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030:By Roots Analysis:
Benefits offered by microbial biomanufacturing, such as lowproduction costs and faster development timelines, have led many innovators toadopt these platforms for next generation biologics, offering lucrativeopportunities for CMOs / CDMOs
Roots Analysis is pleased toannounce the publication of its recent study, titled, “MicrobialContract Biomanufacturing Market,2020-2030.
The report features an extensive study of the currentmarket landscape and future opportunities associated with the microbialcontract biomanufacturing market. It features a detailed analysis of keydrivers and trends related to this evolving domain. In addition to otherelements, the study includes:
§ Adetailed review of the current landscape of companies offering contractmanufacturing services.
§ Elaborateprofiles of key players that specialize in offering services for contract biomanufacturing.
§ A competitivenessanalysis, highlighting key players engaged in microbial based contractmanufacturing, featuring insightful pictorial summaries and representations.
§ Ananalysis of the partnerships and expansions that have been established in thisdomain, in the recent past.
§ A competitivenessanalysis, highlighting key players engaged in microbial based contractmanufacturing, featuring insightful pictorial summaries and representations.
§ Adetailed proprietary 2×2 representation to assess the current market scenario
§ Ananalysis of the initiatives of big biopharma players engaged in this domain.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
§ Type of Product
§ API
§ FDF
§ Type of Biologic
§ Proteins
§ Enzymes
§ Growth Hormones
§ Antibody based Drugs
§ Others (plasmidDNA, probiotics, microbiome-based biologics)
§ Type of MicrobialExpression System
§ Bacteria
§ Yeast
§ Others (Algae andfungi)
§ Scale of Operation
§ Commercial
§ Preclinical /Clinical
§ Type of End User
§ Small Companies
§ Mid-sized Companies
§ Large / Very LargeCompanies
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia Pacific
§ Middle East and NorthAfrica
§ Latin America
Transcripts of interviews heldwith the following senior level representatives of stakeholder companies
§ Gaurav Kaushik (ChiefExecutive Officer and Managing Director, MeteoricBiopharmaceuticals)
§ Debbie Pinkston (VicePresident, Sales and Business Development, List Biological Laboratories)
§ Andrea Conforto(Sales and Marketing, Bioservices Director, Olon)
§ Max Rossetto (GeneralManager, Business Development, Luina Bio)
§ Rob van Dijk(Business Development Manager, WACKERBiotech)
Keycompanies covered in the report
§ AGC Biologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ NorthwayBiotechpharma
§ Ology Bioservices
§ Porton Biopharma
§ Stelis Biopharma
Foradditional details, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html oremail sales@rootsanalysis.com
Youmay also be interested in the following titles:
1. DrugRepurposing Service Providers Market, 2020 – 2030
2. AntibodyDiscovery Services and Platforms Market (3rd Edition), 2020-2030
3. LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on ActivePharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030
Contact:
GauravChaudhary
+1(415) 800 3415
+44(122) 391 1091
